Technical Analysis for FATE - Fate Therapeutics, Inc.

Grade Last Price % Change Price Change
grade A 22.5 1.08% 0.24
FATE closed up 1.08 percent on Thursday, July 18, 2019, on 79 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical FATE trend table...

Date Alert Name Type % Chg
New 52 Week Closing High Bullish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Overbought Stochastic Strength 0.00%
New 52 Week High Strength 1.08%
Upper Bollinger Band Walk Strength 1.08%
Overbought Stochastic Strength 1.08%
Upper Bollinger Band Touch Strength 1.08%
New 52 Week Closing High Bullish 0.18%
New 52 Week High Strength 0.18%
Stochastic Reached Overbought Strength 0.18%

Older signals for FATE ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its HSC modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person's lifespan; and SSC modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person's lifespan. The company's products include ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical trials for hematologic malignancies in adult patients. It also plans to conduct clinical trials of ProHema for hematopoietic reconstitution in hematologic malignancies and lysosomal storage disorders in pediatric patients. In addition, the company is developing Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Biotechnology Biopharmaceutical Life Sciences Biology Stem Cells Hematologic Malignancies Orphan Diseases Cord Blood Induced Stem Cells Adult Stem Cell Lysosomal Storage Disorders
Is FATE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 22.82
52 Week Low 8.64
Average Volume 792,669
200-Day Moving Average 16.2721
50-Day Moving Average 19.382
20-Day Moving Average 20.821
10-Day Moving Average 21.409
Average True Range 1.0795
ADX 35.32
+DI 27.6245
-DI 9.7014
Chandelier Exit (Long, 3 ATRs ) 19.5815
Chandelier Exit (Short, 3 ATRs ) 22.0385
Upper Bollinger Band 22.8425
Lower Bollinger Band 18.7995
Percent B (%b) 0.92
BandWidth 19.417895
MACD Line 0.8672
MACD Signal Line 0.7361
MACD Histogram 0.1311
Fundamentals Value
Market Cap 931.82 Million
Num Shares 41.4 Million
EPS -0.96
Price-to-Earnings (P/E) Ratio -23.44
Price-to-Sales 42.87
Price-to-Book 3.19
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 23.66
Resistance 3 (R3) 23.57 23.10 23.46
Resistance 2 (R2) 23.10 22.81 23.14 23.40
Resistance 1 (R1) 22.80 22.62 22.95 22.89 23.33
Pivot Point 22.33 22.33 22.41 22.37 22.33
Support 1 (S1) 22.03 22.04 22.18 22.12 21.67
Support 2 (S2) 21.56 21.85 21.60 21.60
Support 3 (S3) 21.26 21.56 21.54
Support 4 (S4) 21.35